Concept
Rheumatoid arthritis
Rheumatoid arthritis is a chronic inflammatory joint disease. Study layers here separate three claims: a RIPK1 inhibitor experimental-medicine RCT without meaningful mean efficacy at tested exposures, a phase 1b MTD for a fibroblast-aimed CDK inhibitor in TNF-refractory disease, and early synovial biopsy evidence of molecular/histologic heterogeneity.
Students meet “new RA targets” as one pipeline story. A null RIPK1 efficacy signal, a seliciclib dose-finding result, and early synovium clusters answer different development questions. Mixing them invents false agreement about what works.
Evidence
What the evidence shows
Drawn from 3 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
GSK2982772 (RIPK1) looked similar to placebo on RA activity at tested exposures.
In a 52-patient placebo-controlled experimental-medicine study on stable csDMARDs, safety was primary and DAS28-CRP/ACR outcomes were similar between GSK2982772 and placebo — authors conclude no meaningful clinical improvement at evaluated exposures.
- Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)— different development stage/target — open-label MTD for a CDK/fibroblast strategy, not RIPK1 efficacy
- Early RA synovium splits into two expression/histology groups— tissue heterogeneity biology, not a drug RCT
Study Role Design N Population Outcome RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here Supports RCTMulticenter double-blind placebo-controlled experimental-medicine RCT; 2:1 drug:placebo for 84 days on stable csDMARD N=52 · 34 GSK2982772 60 mg, 18 placebo Adults with rheumatoid arthritis on stable conventional DMARD therapy Safety/PK and preliminary DAS28-CRP / ACR efficacy Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b) Qualifiesdifferent development stage/target — open-label MTD for a CDK/fibroblast strategy, not RIPK1 efficacy Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target Adults with active RA despite ≥3 months stable anti-TNF therapy Maximum tolerated dose (dose-limiting toxicity) Early RA synovium splits into two expression/histology groups Qualifiestissue heterogeneity biology, not a drug RCT OtherArthroscopic targeted synovial biopsy histopathology + expression clustering N=16 · 12 early RA (<1 year) and 4 long-standing RA; 18 samples from 16 cases Adults with early or long-standing rheumatoid arthritis undergoing targeted synovial biopsy Histopathology and gene-expression subgroups of synovitis Seliciclib’s MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b).
In 15 open-label patients with active RA despite TNF inhibitors, Bayesian dose-finding set seliciclib MTD at 400 mg, aiming at synovial fibroblast proliferation rather than classic immune-cytokine pathways alone.
- RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here— MTD ≠ efficacy; RIPK1 study tested clinical activity and was null at its exposures
Study Role Design N Population Outcome Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b) Supports Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target Adults with active RA despite ≥3 months stable anti-TNF therapy Maximum tolerated dose (dose-limiting toxicity) RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here QualifiesMTD ≠ efficacy; RIPK1 study tested clinical activity and was null at its exposures RCTMulticenter double-blind placebo-controlled experimental-medicine RCT; 2:1 drug:placebo for 84 days on stable csDMARD N=52 · 34 GSK2982772 60 mg, 18 placebo Adults with rheumatoid arthritis on stable conventional DMARD therapy Safety/PK and preliminary DAS28-CRP / ACR efficacy Early RA synovium already shows two expression/histology clusters.
Targeted arthroscopic biopsies from early RA clustered into two major gene-expression groups with different histological scores — molecular heterogeneity early in disease, not a treatment-assignment tool by itself.
- Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)— fibroblast-targeting rationale is related thematically, but TRAFIC is dose-finding in TNF-refractory disease, not early-biopsy clustering
Study Role Design N Population Outcome Early RA synovium splits into two expression/histology groups Supports OtherArthroscopic targeted synovial biopsy histopathology + expression clustering N=16 · 12 early RA (<1 year) and 4 long-standing RA; 18 samples from 16 cases Adults with early or long-standing rheumatoid arthritis undergoing targeted synovial biopsy Histopathology and gene-expression subgroups of synovitis Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b) Qualifiesfibroblast-targeting rationale is related thematically, but TRAFIC is dose-finding in TNF-refractory disease, not early-biopsy clustering Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target Adults with active RA despite ≥3 months stable anti-TNF therapy Maximum tolerated dose (dose-limiting toxicity)
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
A null RIPK1 activity signal, an MTD for seliciclib, and early synovium clusters are different evidence types. Pathway interest does not transfer efficacy across programmes.
- RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here
- Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)
- Early RA synovium splits into two expression/histology groups
Study Role Design N Population Outcome RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here Supports RCTMulticenter double-blind placebo-controlled experimental-medicine RCT; 2:1 drug:placebo for 84 days on stable csDMARD N=52 · 34 GSK2982772 60 mg, 18 placebo Adults with rheumatoid arthritis on stable conventional DMARD therapy Safety/PK and preliminary DAS28-CRP / ACR efficacy Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b) Supports Human experimentPhase 1b TRAFIC: non-randomised open-label Bayesian dose-finding of oral seliciclib N=15 · Five dose cohorts; MTD 400 mg at 35% DLT target Adults with active RA despite ≥3 months stable anti-TNF therapy Maximum tolerated dose (dose-limiting toxicity) Early RA synovium splits into two expression/histology groups Supports OtherArthroscopic targeted synovial biopsy histopathology + expression clustering N=16 · 12 early RA (<1 year) and 4 long-standing RA; 18 samples from 16 cases Adults with early or long-standing rheumatoid arthritis undergoing targeted synovial biopsy Histopathology and gene-expression subgroups of synovitis
Common misconceptions
Any new RA mechanistic trial that enrols patients has shown the drug works.
Safety/MTD studies and null efficacy experimental-medicine trials are not positive efficacy RCTs. Read the primary endpoint.
Early RA synovium is molecularly uniform.
Even early targeted biopsies split into expression/histology groups in this series.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
Why is TRAFIC’s 400 mg MTD not evidence that seliciclib improves DAS28?
Phase 1b dose-finding estimates tolerability; it does not test clinical efficacy against a control for disease activity.
How should a student read the RIPK1 study’s similar DAS28/ACR results?
As a null mean efficacy signal at the tested exposures in an experimental-medicine design — useful pathway information, not proof the pathway can never work at other doses/regimens, and not a positive efficacy win.
The studies
3 studies in this library bear on Rheumatoid arthritis, ordered by citations.
- RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here
In 52 patients with moderate–severe RA on stable csDMARDs, oral GSK2982772 60 mg for 84 days was mainly assessed for safety; DAS28-CRP and ACR responses looked similar to placebo, without meaningful clinical improvement at tested exposures.
- Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)
In an open-label UK dose-finding trial of 15 TNF-refractory RA patients, the CDK inhibitor seliciclib’s maximum tolerated dose was 400 mg, aiming at synovial fibroblast proliferation rather than classic immune-cytokine targets alone.
- Early RA synovium splits into two expression/histology groups
Targeted knee synovial biopsies from early RA patients clustered into two major gene-expression groups with different histological scores, showing molecular heterogeneity even early in disease.
Learn alongside
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published